FDA approves new indication for Grünenthal, Averitas' QutenzaGrünenthal and its U.S. subsidiary, Averitas Pharma’s Qutenza (capsaicin), is the first and only treatment of its kind to deliver prescription-strength capsaicin directly into the skin. Mylan, Upjohn unveil branding for ViatrisViatris’ platform will provide a unique global healthcare gateway that will offer partners ready access to more markets and patients worldwide. Xeris debuts Gvoke HypoPen Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle. FDA approves Rukobia for HIV ViiV Healthcare's Rukobia is a treatment for patients with multidrug-resistant HIV infections. Upsher-Smith offers help to people with migraines during Migraine Month Upsher-Smith's Access Pathways Program offers patient savings and support services for patients who need migraine medications. Novartis receives FDA nod for new indication of Cosentyx The indication to treat non-radiographic axial spondyloarthritis is the fourth FDA-approved indication for Novartis’ Cosentyx. Abbott gets FDA clearance for FreeStyle Libre 2 Abbott's FreeStyle Libre 2 continuous glucose monitoring system does not require fingersticks. Dr. Reddy's inks licensing deal with Gilead for remdesivir Dr. Reddy's will manufacture remdesivir, Gilead's investigational antiviral therapy used to treat COVID-19. Chiesi Group gets FDA blessing for new formulation of Ferriprox Chiesi Group’s Ferriprox (deferiprone) comes in twice a day 1,000-mg oral tablets, eliminating the midday dose. 2 Lilly drugs get new indications The FDA has given the green light for new indication's for Lilly's Cyramz, and Taltz. First Previous 27 28 29 30 31 Next Last